All news

Geron flags RYTELO growth, European launch plans

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

Geron Corporation told the Stifel 2026 Healthcare Conference that RYTELO, its lower-risk myelodysplastic syndrome treatment, posted fourth-quarter net revenue above $60 million with an expanding prescriber base. The company plans a German launch by year-end 2026 and France in 2027, while discontinuing the IMpactMF trial to concentrate on RYTELO growth and business development.

Read original source

SFB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.